Check out the companies that made headlines before the bell. Crypto Stocks – Stocks associated with cryptocurrencies rose as Bitcoin rose above $64,000 earlier in the week. Extending gains from the previous session, MicroStrategy and Mara Holdings — formerly Marathon Digital — each gained more than 5%, while Coinbase advanced more than 3%. FanDuel's parent company popped 4% after Flutter Entertainment – Wells Fargo upgraded shares to overweight, saying investors should consider buying the stock after a recent sell-off. Boeing – Shares fell 2.3% on Friday afternoon after the plane maker announced it plans to cut about 10% of its workforce, or about 17,000 people. Boeing also suspended deliveries of its still-uncertified 777X wide-body plane and forecast a wider-than-expected loss for the third quarter. The company is facing mounting losses amid the ongoing machinist strike. Sirius XM Holdings – The audio entertainment company rose 3.5% after Warren Buffett's Berkshire Hathaway revealed it had bought more stock. Berkshire bought about 3.6 million shares of Sirius last week, bringing its total holdings to more than 108 million shares, according to a securities filing. Caterpillar – The industrial company slipped more than 2% after Morgan Stanley downgraded shares from equal weight to underweight. The investment bank cited possible de-stocking ahead and a negative risk-reward backdrop for the stock. Ibotta – Shares popped nearly 4% after Goldman Sachs upgraded Ibotta to buy from neutral, saying the mobile company offering cash back rewards to users has an “attractive risk/reward” at its current valuation. The Wall Street firm cited the company's growth opportunities through partnerships with Walmart and Instacart. Aplowin – The mobile technology stock lost 3.7% as Goldman Sachs turned neutral from buy. After steep recent outperformance, the bank said Aplovin's risk-to-reward ratio is more balanced. Hims and Hers Health — Shares rose more than 6% after the Food and Drug Administration said it allowed compounding pharmacies — which sell custom-made drugs — to sell their own version of Eli Lilly's weight-loss drug Mounjaro. — CNBC's Alex Haring, Samantha Subin, Jesse Pound, Sarah Min, Hakyung Kim and Pia Singh contributed reporting.
